Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study

Purpose To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). Methods Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab ( n  = 25) or i...

Full description

Saved in:
Bibliographic Details
Published in:Graefe's archive for clinical and experimental ophthalmology 2017-10, Vol.255 (10), p.1899-1905
Main Authors: Chatziralli, Irini, Theodossiadis, George, Kabanarou, Stamatina A., Parikakis, Efstratios, Xirou, Tina, Mitropoulos, Panagiotis, Theodossiadis, Panagiotis
Format: Article
Language:English
Subjects:
Acuity
Aged
Angiogenesis Inhibitors - administration & dosage
Dexamethasone
Dexamethasone - administration & dosage
Dose-Response Relationship, Drug
Drug Implants
Edema
Female
Glucocorticoids - administration & dosage
Humans
Immunotherapy
Intravitreal Injections
Male
Medicine
Medicine & Public Health
Middle Aged
Monoclonal antibodies
Occlusion
Ophthalmology
Prospective Studies
Ranibizumab - administration & dosage
Retina
Retinal Disorders
Retinal Vein Occlusion - diagnosis
Retinal Vein Occlusion - drug therapy
Retinal Vein Occlusion - physiopathology
Statistical analysis
Steroids
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). Methods Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab ( n  = 25) or intravitreal 0.7 mg dexamethasone implant ( n  = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups. Results At month 12, there was no statistically significant difference in BCVA and CST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group. Conclusions Both ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.
ISSN:0721-832X
1435-702X
DOI:10.1007/s00417-017-3719-5